Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD131
MIFTS: 62

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bladder Urothelial Carcinoma

About this section

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 15
Transitional Cell Carcinoma of the Bladder 30 6
Transitional Cell Carcinoma of Bladder 12 74
Bladder Transitional Cell Carcinoma 12 17
Urinary Bladder Urothelial Carcinoma 12
Carcinoma Transitional Cell Bladder 56
Urothelial Bladder Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4006
NCIt 51 C39851
UMLS 74 C0279680
Sources

Summaries for Bladder Urothelial Carcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to transitional cell carcinoma and adenoma. An important gene associated with Bladder Urothelial Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and testes, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bladder Urothelial Carcinoma

About this section

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 32.0 BRAF ERBB2 FGFR3 HRAS TP53
2 adenoma 30.5 BRAF CTNNB1 KRAS TP53
3 ovarian cancer 1 30.4 AKT1 ERBB2 KRAS PIK3CA TP53
4 undifferentiated pleomorphic sarcoma 30.4 IDH1 KRAS PIK3CA
5 nevus, epidermal 30.2 FGFR3 HRAS KRAS NRAS PIK3CA
6 suppression of tumorigenicity 12 30.0 AKT1 BRAF CTNNB1 HRAS IDH1 PIK3CA
7 retinoblastoma 29.9 HOTAIR MALAT1 MEG3 TP53
8 renal cell carcinoma, nonpapillary 29.7 GAS5 HOTAIR MALAT1 PVT1 TUG1
9 adenocarcinoma 29.2 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
10 squamous cell carcinoma 29.2 AKT1 BRAF CTNNB1 ERBB2 FGFR3 HOTAIR
11 bladder cancer 28.7 ERBB2 FGFR3 GAS5 HOTAIR HRAS KRAS
12 melanoma 28.6 BRAF GAS5 HOTAIR MALAT1 MAP2K1 MEG3
13 prostate cancer 27.9 AKT1 CTNNB1 ERBB2 FGFR1 GAS5 HOTAIR
14 lung cancer 27.4 AKT1 BRAF ERBB2 FGFR1 FGFR3 GAS5
15 non-papillary transitional cell carcinoma of the bladder 12.6
16 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.4
17 clear cell variant infiltrating bladder urothelial carcinoma 12.3
18 non-invasive bladder urothelial carcinoma 12.3
19 micropapillary variant infiltrating bladder urothelial carcinoma 12.3
20 lipid-cell variant infiltrating bladder urothelial carcinoma 12.3
21 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.3
22 nested variant infiltrating bladder urothelial carcinoma 12.3
23 microcystic variant infiltrating bladder urothelial carcinoma 12.3
24 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.3
25 invasive bladder transitional cell carcinoma 11.5
26 small cell carcinoma of the bladder 11.5
27 midline interhemispheric variant of holoprosencephaly 10.8
28 malignant spiradenoma 10.7 PIK3CA TP53
29 non-invasive bladder papillary urothelial neoplasm 10.7 FGFR3 TP53
30 dermatosis papulosa nigra 10.7 FGFR3 PIK3CA
31 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
32 prostate transitional cell carcinoma 10.6 CTNNB1 PIK3CA
33 anal squamous cell carcinoma 10.6 AKT1 PIK3CA TP53
34 epidermolytic nevus 10.6 FGFR3 NRAS
35 male reproductive organ cancer 10.6 AKT1 CTNNB1 TP53
36 splenic diffuse red pulp small b-cell lymphoma 10.6 MAP2K1 TP53
37 ductal carcinoma in situ 10.6 AKT1 ERBB2 TP53
38 gonadal disease 10.6 AKT1 ERBB2 TP53
39 bladder squamous cell carcinoma 10.6 BRAF TP53
40 peripheral nervous system neoplasm 10.6 AKT1 NRAS TP53
41 hepatoblastoma 10.6 CTNNB1 TP53 TUG1
42 cerebellar astrocytoma 10.6 IDH1 TP53
43 intracranial chondrosarcoma 10.6 IDH1 TP53
44 oral cavity cancer 10.6 ERBB2 PIK3CA TP53
45 plagiocephaly 10.6 FGFR1 FGFR3
46 nervous system cancer 10.6 AKT1 IDH1 TP53
47 central nervous system cancer 10.6 AKT1 IDH1 TP53
48 adult hepatocellular carcinoma 10.6 CTNNB1 PIK3CA TP53
49 prostate adenoid cystic carcinoma 10.6 HRAS PIK3CA
50 uterine corpus serous adenocarcinoma 10.5 ERBB2 PIK3CA TP53

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma
Sources

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

About this section

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

27 (show top 50) (show all 61)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.89 BRAF HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.89 KRAS
3 Decreased viability GR00107-A-1 10.89 MAP2K1
4 Decreased viability GR00221-A-1 10.89 HRAS KRAS PIK3CA AKT1 FGFR1 FGFR3
5 Decreased viability GR00221-A-2 10.89 HRAS KRAS PIK3CA AKT1 FGFR1 FGFR3
6 Decreased viability GR00221-A-3 10.89 HRAS AKT1 FGFR3 ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 10.89 BRAF PIK3CA AKT1 ERBB2
8 Decreased viability GR00301-A 10.89 BRAF KRAS
9 Decreased viability GR00342-S-1 10.89 MAP2K1
10 Decreased viability GR00342-S-2 10.89 MAP2K1
11 Decreased viability GR00342-S-3 10.89 MAP2K1
12 Decreased viability GR00381-A-1 10.89 BRAF KRAS
13 Decreased viability GR00402-S-2 10.89 BRAF HRAS KRAS PIK3CA AKT1 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.23 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.23 CTNNB1 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.23 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.23 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.23 PIK3CA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.23 KRAS
20 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.23 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.23 FGFR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.23 IDH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.23 IDH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.23 IDH1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.23 IDH1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.23 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.23 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.23 AKT1 PIK3CA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.23 BRAF PIK3CA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.23 KRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.23 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.23 IDH1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.23 AKT1 BRAF CTNNB1 KRAS PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.23 FGFR1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.23 PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.23 BRAF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.23 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.23 CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.23 KRAS
40 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.23 KRAS
41 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.23 BRAF
42 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.23 BRAF
43 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.23 BRAF
44 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.23 IDH1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.23 AKT1 PIK3CA
46 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.23 FGFR1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.23 BRAF CTNNB1 FGFR1 IDH1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.23 CTNNB1 KRAS PIK3CA
49 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.23 AKT1 KRAS FGFR1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.23 KRAS

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
2 behavior/neurological MP:0005386 10.41 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
3 homeostasis/metabolism MP:0005376 10.41 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
4 cardiovascular system MP:0005385 10.4 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
5 cellular MP:0005384 10.4 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
6 integument MP:0010771 10.36 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
7 mortality/aging MP:0010768 10.36 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
8 craniofacial MP:0005382 10.35 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
9 digestive/alimentary MP:0005381 10.35 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
10 embryo MP:0005380 10.34 AKT1 BRAF CTNNB1 ERBB2 FGFR1 KRAS
11 endocrine/exocrine gland MP:0005379 10.33 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
12 immune system MP:0005387 10.3 AKT1 BRAF CTNNB1 FGFR1 FGFR3 IDH1
13 neoplasm MP:0002006 10.26 AKT1 BRAF CTNNB1 ERBB2 FGFR3 HRAS
14 nervous system MP:0003631 10.23 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
15 normal MP:0002873 10.18 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
16 limbs/digits/tail MP:0005371 10.14 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
17 hearing/vestibular/ear MP:0005377 10.12 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
18 muscle MP:0005369 10.1 AKT1 BRAF CTNNB1 ERBB2 FGFR1 KRAS
19 liver/biliary system MP:0005370 10.07 AKT1 BRAF CTNNB1 KRAS NFE2L2 NRAS
20 no phenotypic analysis MP:0003012 10.03 CTNNB1 FGFR1 FGFR3 HRAS KRAS NRAS
21 reproductive system MP:0005389 9.96 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
22 renal/urinary system MP:0005367 9.92 BRAF CTNNB1 FGFR1 FGFR3 HRAS KRAS
23 respiratory system MP:0005388 9.85 AKT1 BRAF CTNNB1 ERBB2 FGFR3 HRAS
24 skeleton MP:0005390 9.8 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
25 pigmentation MP:0001186 9.77 BRAF CTNNB1 KRAS NRAS TP53
26 vision/eye MP:0005391 9.28 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
Sources

Drugs & Therapeutics for Bladder Urothelial Carcinoma

About this section

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
4
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
5
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
6
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
9
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
10
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
13
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
14
Aminolevulinic acid Approved Phase 3 106-60-5 137
15
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
16
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
17
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
18
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
19
Atezolizumab Approved, Investigational Phase 3,Phase 2 1380723-44-3
20
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
21
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
22
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
25
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
26
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
27
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 388082-78-8, 231277-92-2 208908 9941095
28 Tocotrienol Investigational Phase 3 6829-55-6
29
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31
Levulinic acid Experimental Phase 3 123-76-2 11579
32
Fenretinide Investigational Phase 3 65646-68-6
33 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Liposomal amphotericin B Phase 2, Phase 3
40 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Antioxidants Phase 3
42 Tocopherols Phase 3
43 Vitamins Phase 3
44 Trace Elements Phase 3,Early Phase 1
45 Nutrients Phase 3,Early Phase 1
46 Micronutrients Phase 3,Early Phase 1
47 Tocotrienols Phase 3
48 Protective Agents Phase 3
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
50 Antimitotic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 210)
# Name Status NCT ID Phase Drugs
1 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
2 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
3 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
4 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
5 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
6 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
7 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
8 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Completed NCT00867347 Phase 3
9 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
10 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
11 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
12 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
13 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
14 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
15 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
16 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
17 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
18 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
19 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
20 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
21 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
22 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
23 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
24 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
25 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
26 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
27 Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer Recruiting NCT01812369 Phase 3 GEMCITABINE CISPLATINE;METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
28 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
29 Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Not yet recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
30 S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
31 BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer Terminated NCT00352079 Phase 3 gefitinib
32 Instillation of Gemcitabine in Patients With Superficial Bladder Cancer Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
33 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
34 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
35 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3 mitomycin C
36 Bristol Bladder Trial Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
37 Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
38 PF-03446962 in Relapsed or Refractory Urothelial Cancer Unknown status NCT01620970 Phase 2 PF03446962
39 Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder Unknown status NCT00694915 Phase 2
40 Alisertib in Chemotherapy-pretreated Urothelial Cancer Unknown status NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
41 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
42 Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
43 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
44 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
45 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
46 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
47 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2 Trement
48 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder Completed NCT00963859 Phase 2
49 Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer Completed NCT01118351 Phase 2 sunitinib malate
50 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Sources

Genetic Tests for Bladder Urothelial Carcinoma

About this section

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 30
Sources

Anatomical Context for Bladder Urothelial Carcinoma

About this section

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

42
Prostate, Kidney, Testes, Lung, Lymph Node, Endothelial, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

20
The Lining Of The Bladder
Sources

Publications for Bladder Urothelial Carcinoma

About this section

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 1053)
# Title Authors Year
1
Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma. ( 30602154 )
2019
2
The Landscape of Chimeric RNAs in Bladder Urothelial Carcinoma. ( 30818082 )
2019
3
The long non-coding RNA LINC00460 predicts the prognosis and promotes the proliferation and migration of cells in bladder urothelial carcinoma. ( 30881506 )
2019
4
Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. ( 30630456 )
2019
5
The impact of narrow band imaging (NBI) in the detection and resection of bladder tumour in transitional cell carcinoma of the bladder: A prospective, blinded, sequential intervention randomized controlled trial. ( 30822478 )
2019
6
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors? ( 29130135 )
2018
7
Quantitative proteomic analysis identifies AHNAK as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. ( 29950347 )
2018
8
RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-I_B pathway. ( 29867225 )
2018
9
Nkx2.8 inhibits epithelial-mesenchymal transition in bladder urothelial carcinoma via transcriptional repression of Twist1. ( 29311157 )
2018
10
Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma. ( 29695918 )
2018
11
Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway. ( 29670371 )
2018
12
SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival. ( 29662193 )
2018
13
Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. ( 29937935 )
2018
14
Upregulation of Arp2 expression is associated with the prognosis and prediction of lymph node metastasis in bladder urothelial carcinoma. ( 29593429 )
2018
15
Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis. ( 29391889 )
2018
16
Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma. ( 29936478 )
2018
17
Combined use of urinary Survivin detection and liquid-based cytology for the early diagnosis of bladder urothelial carcinoma. ( 29725469 )
2018
18
Expression of PLAGL2 in bladder urothelial carcinoma and its relationship to lymph node metastasis and survival. ( 29662235 )
2018
19
LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression. ( 29496693 )
2018
20
Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. ( 29416608 )
2018
21
Clinical and cytopathological factors affecting the cellularity of urinary cell blocks and the implication for the diagnosis and follow-up of the urinary bladder urothelial carcinoma. ( 29873845 )
2018
22
Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker. ( 29544183 )
2018
23
Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy. ( 29084921 )
2018
24
miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells. ( 29379304 )
2018
25
Proteomic Identification of the Galectin-1-Involved Molecular Pathways in Urinary Bladder Urothelial Carcinoma. ( 29671787 )
2018
26
Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma. ( 29702555 )
2018
27
Fibroblasts from pBOO promote tumorigenesis by secreting TGFbeta1 to induce EMT in bladder urothelial carcinoma cells. ( 29934361 )
2018
28
Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. ( 30352907 )
2018
29
RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update. ( 30359990 )
2018
30
Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1. ( 30461333 )
2018
31
Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. ( 30548659 )
2018
32
MRS1754 inhibits proliferation and migration of bladder urothelial carcinoma by regulating mitogen-activated protein kinase pathway. ( 30565699 )
2018
33
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. ( 30017405 )
2018
34
The effect of marital status on the survival of patients with bladder urothelial carcinoma: A SEER database analysis. ( 30024509 )
2018
35
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. ( 30038717 )
2018
36
Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. ( 30048970 )
2018
37
TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation. ( 30075204 )
2018
38
Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma. ( 30341375 )
2018
39
Enterovesical Fistula Secondary to Transitional Cell Carcinoma of the Bladder. ( 30474067 )
2018
40
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( 30279015 )
2018
41
Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-I_B/MMP-7 signaling pathway. ( 28333147 )
2017
42
Identification and functional analysis of risk-related microRNAs for the prognosis of patients with bladder urothelial carcinoma. ( 29344166 )
2017
43
Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma. ( 28488128 )
2017
44
Bladder urothelial carcinoma extending to rectal mucosa and presenting with rectal bleeding. ( 28690772 )
2017
45
The expression and clinical significance of ZBTB7 in transitional cell carcinoma of the bladder. ( 29085492 )
2017
46
Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. ( 28600503 )
2017
47
Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. ( 28347658 )
2017
48
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. ( 28417194 )
2017
49
Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited doxorubicin resistance of bladder urothelial carcinoma via Wnt/I^-catenin pathway. ( 29179467 )
2017
50
Association Between Human Papillomavirus and Transitional Cell Carcinoma of the Bladder. ( 29101759 )
2017
Sources

Variations for Bladder Urothelial Carcinoma

About this section

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 555)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
4 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
5 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
6 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
7 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
10 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
11 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
12 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
13 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh38 Chromosome 17, 7674250: 7674250
14 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
15 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh38 Chromosome 17, 7673764: 7673764
16 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
17 TP53 NM_000546.5(TP53): c.814G> A (p.Val272Met) single nucleotide variant Uncertain significance rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
18 TP53 NM_000546.5(TP53): c.814G> A (p.Val272Met) single nucleotide variant Uncertain significance rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
19 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
20 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
21 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
22 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
23 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh37 Chromosome 17, 7578403: 7578403
24 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh38 Chromosome 17, 7675085: 7675085
25 TP53 NM_000546.5(TP53): c.431A> C (p.Gln144Pro) single nucleotide variant Uncertain significance rs786203071 GRCh37 Chromosome 17, 7578499: 7578499
26 TP53 NM_000546.5(TP53): c.431A> C (p.Gln144Pro) single nucleotide variant Uncertain significance rs786203071 GRCh38 Chromosome 17, 7675181: 7675181
27 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
28 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
29 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
30 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh37 Chromosome 17, 7577114: 7577114
31 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
32 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
33 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
34 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
35 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh38 Chromosome 17, 7674263: 7674263
36 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh37 Chromosome 17, 7577581: 7577581
37 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
38 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
39 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
40 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
41 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
42 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
43 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
44 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
45 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
46 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
47 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
48 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
49 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
50 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
Sources

Expression for Bladder Urothelial Carcinoma

About this section
Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.
Sources

Pathways for Bladder Urothelial Carcinoma

About this section

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.21 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
2
ERK Signaling 65
Show member pathways
 14.03 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
3
Apoptotic Pathways in Synovial Fibroblasts 65
Show member pathways
 14.01 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
4
HIV Life Cycle 67
Show member pathways
 13.91 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
5
GPCR Pathway 65
Show member pathways
 13.89 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
6
PEDF Induced Signaling 65
Show member pathways
 13.86 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
7
Activation of cAMP-Dependent PKA 65
Show member pathways
 13.75 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
8
TGF-Beta Pathway 65
Show member pathways
 13.74 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
9
Developmental Biology 67
Show member pathways
 13.7 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
10
Class I MHC mediated antigen processing and presentation 67
Show member pathways
 13.64 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
11
Akt Signaling 65
Show member pathways
 13.57 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
12
Integrin Pathway 65
Show member pathways
 13.56 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
13
Cytokine Signaling in Immune system 67
Show member pathways
 13.56 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
14
CREB Pathway 65
Show member pathways
 13.5 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
15
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.49 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
16
PAK Pathway 65
Show member pathways
 13.48 AKT1 CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
17
IL-2 Pathway 65
Show member pathways
 13.4 AKT1 BRAF ERBB2 HRAS KRAS MAP2K1
18
Phospholipase-C Pathway 65
Show member pathways
 13.29 AKT1 BRAF FGFR1 FGFR3 HRAS KRAS
19
G-Beta Gamma Signaling 65
Show member pathways
 13.27 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
20
p70S6K Signaling 65
Show member pathways
 13.24 AKT1 FGFR1 FGFR3 HRAS KRAS MAP2K1
21
fMLP Pathway 65
Show member pathways
 13.23 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
22
PI3K-Akt signaling pathway 38
Show member pathways
 13.21 AKT1 CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
23
Circadian entrainment 38
Show member pathways
 13.18 AKT1 HRAS KRAS MAP2K1 NRAS PIK3CA
24
TNFR1 Pathway 65
Show member pathways
 13.17 AKT1 CTNNB1 HRAS KRAS MAP2K1 NRAS
25
Human cytomegalovirus infection 38
Show member pathways
 13.17 AKT1 CTNNB1 HRAS KRAS MAP2K1 NRAS
26
Development Angiotensin activation of ERK 23
Show member pathways
 13.14 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
27
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.13 AKT1 BRAF ERBB2 HRAS KRAS MAP2K1
28
Sertoli-Sertoli Cell Junction Dynamics 65
Show member pathways
 13.12 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
29
Focal Adhesion 1 38
Show member pathways
 13.11 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
30
CCR5 Pathway in Macrophages 65
Show member pathways
 13.09 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
31
TCR Signaling (Qiagen) 65
Show member pathways
 13.08 AKT1 HRAS KRAS MAP2K1 NRAS TP53
32
NFAT and Cardiac Hypertrophy 65
Show member pathways
 13.08 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
33
Endometrial cancer 38
Show member pathways
 13.06 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
34
Downstream signaling of activated FGFR2 67
Show member pathways
 13.04 FGFR1 FGFR3 HRAS KRAS NRAS PIK3CA
35
Apoptosis Modulation and Signaling 1
Show member pathways
 13.03 AKT1 HRAS KRAS MAP2K1 NRAS PIK3CA
36
Beta-Adrenergic Signaling 65
Show member pathways
 13.02 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
37
MAPK-Erk Pathway 68
Show member pathways
 13 BRAF HRAS KRAS MAP2K1 NRAS PIK3CA
38
MAPK signaling pathway 1 38
12.99 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
39
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.97 AKT1 BRAF HRAS KRAS MAP2K1 PIK3CA
40
Ras signaling pathway 38
Show member pathways
 12.95 AKT1 BRAF CTNNB1 FGFR1 FGFR3 HRAS
41
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.94 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
42
Vascular smooth muscle contraction 38
Show member pathways
 12.93 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
43
Development HGF signaling pathway 23
Show member pathways
 12.93 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
44
4-1BB Pathway 65
Show member pathways
 12.91 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
45
Pathways in cancer 38
12.91 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
46
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.9 AKT1 CTNNB1 HRAS KRAS MAP2K1 NRAS
47
Glioma 38
Show member pathways
 12.87 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
48
G-AlphaQ Signaling 65
Show member pathways
 12.86 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
49
Regulation of actin cytoskeleton 38 1
12.85 BRAF FGFR1 FGFR3 HRAS KRAS MAP2K1
50
Gastric cancer 38
Show member pathways
 12.85 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
Sources

GO Terms for Bladder Urothelial Carcinoma

About this section

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.92 AKT1 ERBB2 HRAS KRAS
2 protein autophosphorylation GO:0046777 9.9 AKT1 ERBB2 FGFR1 FGFR3
3 positive regulation of protein kinase B signaling GO:0051897 9.89 ERBB2 FGFR1 FGFR3 PIK3CA
4 negative regulation of gene expression GO:0010629 9.89 AKT1 CTNNB1 FGFR1 HRAS MAP2K1
5 cell differentiation GO:0030154 9.87 AKT1 BRAF CTNNB1 TP53
6 negative regulation of neuron apoptotic process GO:0043524 9.86 BRAF HRAS KRAS PIK3CA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 AKT1 BRAF PIK3CA
8 cellular response to hypoxia GO:0071456 9.84 AKT1 MALAT1 NFE2L2 TP53
9 cellular response to drug GO:0035690 9.83 BRAF NFE2L2 TP53
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.82 HRAS KRAS NRAS
11 phosphatidylinositol phosphorylation GO:0046854 9.81 ERBB2 FGFR1 FGFR3 PIK3CA
12 cellular response to growth factor stimulus GO:0071363 9.8 AKT1 CTNNB1 ERBB2
13 peptidyl-tyrosine phosphorylation GO:0018108 9.8 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
14 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.79 FGFR1 FGFR3 PIK3CA
15 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 AKT1 FGFR1 NFE2L2
16 thymus development GO:0048538 9.75 BRAF CTNNB1 MAP2K1
17 Ras protein signal transduction GO:0007265 9.73 HRAS KRAS NRAS TP53
18 phosphatidylinositol 3-kinase signaling GO:0014065 9.7 AKT1 ERBB2 PIK3CA
19 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.67 AKT1 NFE2L2
20 positive regulation of phospholipase C activity GO:0010863 9.67 FGFR1 HRAS
21 negative regulation of apoptotic process GO:0043066 9.67 AKT1 BRAF CTNNB1 TP53
22 anoikis GO:0043276 9.66 AKT1 PIK3CA
23 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.66 MAP2K1 TP53
24 lung-associated mesenchyme development GO:0060484 9.65 CTNNB1 FGFR1
25 positive regulation of phospholipase activity GO:0010518 9.65 FGFR1 FGFR3
26 positive regulation of MAPK cascade GO:0043410 9.65 CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
27 regulation of axon regeneration GO:0048679 9.64 BRAF MAP2K1
28 response to isolation stress GO:0035900 9.63 HRAS KRAS
29 trachea formation GO:0060440 9.62 CTNNB1 MAP2K1
30 positive regulation of MAP kinase activity GO:0043406 9.62 ERBB2 FGFR1 HRAS KRAS
31 positive regulation of gene expression GO:0010628 9.61 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
32 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.46 BRAF FGFR3 HRAS MAP2K1
33 MAPK cascade GO:0000165 9.23 BRAF ERBB2 FGFR1 FGFR3 HRAS KRAS
34 positive regulation of cell proliferation GO:0008284 10.02 AKT1 CTNNB1 FGFR1 FGFR3 HRAS KRAS
35 phosphorylation GO:0016310 10.02 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
36 cell proliferation GO:0008283 10 AKT1 CTNNB1 ERBB2 HRAS TP53
37 protein phosphorylation GO:0006468 10 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 9.8 CTNNB1 ERBB2 HRAS MAP2K1
2 protein kinase activity GO:0004672 9.8 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
3 kinase activity GO:0016301 9.8 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
4 protein phosphatase binding GO:0019903 9.69 CTNNB1 ERBB2 TP53
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 ERBB2 FGFR1 FGFR3
6 1-phosphatidylinositol-3-kinase activity GO:0016303 9.54 FGFR1 FGFR3 PIK3CA
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 ERBB2 FGFR1 FGFR3 PIK3CA
8 fibroblast growth factor-activated receptor activity GO:0005007 9.4 FGFR1 FGFR3
9 protein tyrosine kinase activity GO:0004713 9.35 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
10 nucleotide binding GO:0000166 9.28 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
11 ATP binding GO:0005524 10.03 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
12 identical protein binding GO:0042802 10 AKT1 BRAF ERBB2 FGFR1 FGFR3 IDH1
Sources

Sources for Bladder Urothelial Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....